Targovax granted US Patent for oncolytic virus ONCOS-102
(Thomson Reuters ONE) -
Oslo, 14 June 2016: Targovax announced today that the US Patent and Trademark
office has granted US patent no 9,345,787 for Targovax' lead viral product
ONCOS-102.
ONCOS-102 is a purposefully engineered human serotype 5 adenovirus optimized to
induce systemic anti-tumor T cell response in cancer patients.
"This patent is an important component of Targovax's intellectual property
portfolio covering specific vaccine candidates," says Antti Vuolanto, Executive
Vice President of Targovax. "We have now confirmed patent protection of our lead
viral product candidate until 2029 in the US which is the biggest market for
immune oncology products."
The main characteristics of ONCOS-102 include:
* The adenovirus knob protein targeting the virus into the host cells is
replaced with a protein from different adenovirus (serotype 3) to facilitate
the specific entrance of ONCOS-102 into tumor cells
* One of the genes affecting virus replication in the host cells is
inactivated (D24 deletion). As a result, the virus cannot replicate in
normal cells, but can do so in tumor cells
* A gene coding for GM-CSF, a drug stimulating the immune response, inserted
into the virus genome and expressed during the virus replication in the
tumor cells
In a previous Phase I trial, ONCOS-102 treatment induced tumor specific immune
activation both at a systemic and lesional level. The immune activation was
associated with clinical benefit.
During 2016, Targovax aims to initiate four clinical Phase I and I/II trials in
several indications to study ONCOS-102 in combination with other treatments such
as immune checkpoint inhibitors, DC therapy and chemotherapy.
For further information, please contact:
Gunnar Gårdemyr, CEO
Phone: +46 73 083 77 79
Email: ggardemyr(at)targovax.com
Øystein Soug, CFO
Phone: +47 906 56 525
Email: oystein.soug(at)targovax.com
Arming the patient's immune system to fight cancer
Targovax is a clinical stage immuno-oncology company developing targeted
immunotherapy treatments for cancer patients. Targovax has a broad and
diversified immune therapy portfolio and aims to become a world leader in its
area. The company is currently developing two complementary and highly targeted
approaches in immuno-oncology.
ONCOS - 102 is a virus-based immunotherapy platform based on engineered
oncolytic viruses armed with potent immune-stimulating transgenes targeting
solid tumors. This treatment is designed to reactivate the immune system's
capacity to recognize and attack cancer cells.
TG01 and TG02 are part of a peptide-based immunotherapy platform targeting the
difficult to treat RAS mutations found in more than 85% of pancreatic cancers,
50% of colorectal cancer and 20-30% of all cancers. Targovax is working towards
demonstrating that TG vaccines will prolong time to cancer progression and
increase survival.
These product candidates will be developed in combination with multiple
treatments, including checkpoint inhibitors in several cancer indications.
Targovax also has a number of other cancer immune therapy candidates in the
early stages of development.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Targovax ASA via GlobeNewswire
[HUG#2020286]
Unternehmensinformation / Kurzprofil:
Datum: 14.06.2016 - 08:00 Uhr
Sprache: Deutsch
News-ID 477473
Anzahl Zeichen: 4118
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 222 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Targovax granted US Patent for oncolytic virus ONCOS-102"
steht unter der journalistisch-redaktionellen Verantwortung von
Targovax ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
